Hosted on MSN20h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment JumpsAclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
GlobalData on MSN21h
Aclaris Therapeutics secures global rights to Biosion’s antibodiesAclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...
Leerink Partners has recently raised Aclaris Therapeutics Inc (ACRS) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on Today, Jefferies had raised the stock from a ...
Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...
Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...
In a report released yesterday, Christopher Raymond from Piper Sandler upgraded Aclaris Therapeutics (ACRS – Research Report) to a Buy, with a ...
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback